A study looking at everolimus for neuroendocrine tumours of the pancreas (The OBLIQUE study)

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Neuroendocrine tumour (NET)




Phase 4

This study is to find out more about the drug everolimus (also known Afinitor) as a treatment for neuroendocrine tumours of the pancreas.

Neuroendocrine tumours (NETs) are a rare group of cancers that make and release hormones. They are normally found in the digestive system Open a glossary item. This trial is looking at neuroendocrine tumours of the pancreas.

Doctors may treat neuroendocrine tumours of the pancreas with a drug called everolimus. It is a type of biological therapy. It stops a protein called mTOR from working properly which can help to stop cancer growing.

We know that everolimus can help people who have pancreatic neuroendocrine tumours that can’t be removed with surgery, or have spread to another part of the body. In this study, researchers want to

  • Learn more about how everolimus affects people’s quality of life Open a glossary item
  • See how well it works in the long term for pancreatic neuroendocrine tumours

Who can enter

You may be able to join this study if all of the following apply

  • You have a neuroendocrine tumour of the pancreas that can’t be removed with surgery, or has spread to another part of your body
  • A scan shows that your cancer is getting worse
  • You are going to start taking everolimus
  • If you take drugs called somatostatin analogues to control symptoms, you must have been on a stable dose for at least 2 months
  • You are at least 18 years old

You cannot join this study if you can’t take everolimus for some reason (your doctor can advise you about this).

Trial design

This phase 4 trial will recruit up to 40 people. Everybody taking part has everolimus.

The study team will collect information from your routine hospital appointments and tests for the first 3 years you take everolimus. If you stop taking everolimus during that time, they will collect information for a month after you stop the treatment.

They will also ask you to fill out some questionnaires before you start treatment, each time you go to hospital in the first 6 months, and a month after you stop taking everolimus (if this happens within the first 3 years).

The questionnaires will ask about side effects and how you’ve been feeling.  This is called a quality of life study.

You complete the questionnaires on a computer at the hospital. A member of the study team will help you with using the computer.

Hospital visits

There are no extra hospital visits. You complete the quality of life questionnaires at planned hospital appointments.

Side effects

We have more information about the possible side effects of everolimus.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr J. Ramage

Supported by

Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 11140

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page